| ²é¿´: 909 | »Ø¸´: 5 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
||
|
However, an evaluation of all reports related to skin events received by Novartis from marketed use of vildagliptin (includes Galvus and Eucreas) since the original placing on the market to 29 Feb 2012 was performed and as post-marketing experience ¡°Localized exfoliation or blisters¡± (frequency not known) were added as the adverse drug reactions in the current CDS. ·ÖÎö¾ä×ӳɷݼӷÒ룬лл£¡ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
¾«Æ··Ò뼯½õ |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ÎäÀí085500»úеרҵ×Ü·Ö300Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏѧÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ4È˻ظ´
281Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0805 316Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
085601Çóµ÷¼Á×Ü·Ö293Ó¢Ò»Êý¶þ
ÒѾÓÐ3È˻ظ´
08¹¤Ñ§µ÷¼Á
ÒѾÓÐ17È˻ظ´
340Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
311Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
ʳƷר˶ һ־Ը˫һÁ÷ 328
ÒѾÓÐ4È˻ظ´
qin20010
ľ³æ (СÓÐÃûÆø)
Сľ³æ²©Ê¿Éúµ¼Ê¦
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2012.8
- Ìû×Ó: 275
- ÔÚÏß: 27.4Сʱ
- ³æºÅ: 346589
- ×¢²á: 2007-04-15
- ÐÔ±ð: GG
- רҵ: ´ß»¯»¯Ñ§

2Â¥2012-06-25 10:59:20
wqssfj1
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 1
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 5947.4
- É¢½ð: 21
- ºì»¨: 3
- Ìû×Ó: 1448
- ÔÚÏß: 252.5Сʱ
- ³æºÅ: 1391164
- ×¢²á: 2011-09-05
- רҵ: Ò©Îï×ÊÔ´
3Â¥2012-06-25 13:15:47
17953216334
Òø³æ (СÓÐÃûÆø)
- ·ÒëEPI: 1
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ½ð±Ò: 1241.8
- ºì»¨: 3
- Ìû×Ó: 130
- ÔÚÏß: 116.5Сʱ
- ³æºÅ: 1787064
- ×¢²á: 2012-04-30
- רҵ: ¸ß·Ö×ÓÖú¼Á
4Â¥2012-06-25 13:24:01
readbycandle
ľ³æ (ÖøÃûдÊÖ)
A thinking worm
- ·ÒëEPI: 55
- Ó¦Öú: 22 (СѧÉú)
- ¹ó±ö: 0.2
- ½ð±Ò: 7100.6
- ºì»¨: 13
- Ìû×Ó: 2158
- ÔÚÏß: 460.5Сʱ
- ³æºÅ: 1793835
- ×¢²á: 2012-05-03
- רҵ: ÃÀ¹úÎÄѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
However, an evaluation of all reports related to skin events received by Novartis from marketed use of vildagliptin (includes Galvus and Eucreas) since the original placing on the market to 29 Feb 2012 was performed and as post-marketing experience ¡°Localized exfoliation or blisters¡± (frequency not known) were added as the adverse drug reactions in the current CDS. ÕâÊÇÁ½¸ö²¢Áеľä×Ó¡£an evaluationketed....was performed and ¡°Localized exfoliation or blisters¡± were added . ·Ò룺 However, an evaluation of all reports related to skin events received by Novartis from marketed use of vildagliptin (includes Galvus and Eucreas) since the original placing on the market to 29 Feb 2012 was performed ²»¹ý£¬ÒѶÔ×ÔͶ·ÅÊг¡ÒÔÀ´ÖÁ2012Äê2ÔÂ29ÈÕŵ»ª¹«Ë¾ÊÕµ½µÄ¹ØÓÚʹÓÃvildagliptin (°üÀ¨Galvus and Eucreas)ÒýÆðµÄƤ·ô·´Ó¦µÄËùÓб¨¸æ½øÐÐÁËÆÀ¹À£¬ and as post-marketing experience ¡°Localized exfoliation or blisters¡± (frequency not known) were added as the adverse drug reactions in the current CDS. ²¢½«¡°¿ÉÒÔÒýÆð¾Ö²¿ÍÑÆ¤»òË®ÅÝ¡±×÷ΪÊг¡·´À¡ÐÅÏ¢¼ÓÈëĿǰCDSµÄ¸±×÷ÓÃ˵Ã÷ÖС£ |
5Â¥2012-06-28 17:36:35
readbycandle
ľ³æ (ÖøÃûдÊÖ)
A thinking worm
- ·ÒëEPI: 55
- Ó¦Öú: 22 (СѧÉú)
- ¹ó±ö: 0.2
- ½ð±Ò: 7100.6
- ºì»¨: 13
- Ìû×Ó: 2158
- ÔÚÏß: 460.5Сʱ
- ³æºÅ: 1793835
- ×¢²á: 2012-05-03
- רҵ: ÃÀ¹úÎÄѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
wqssfj1: ½ð±Ò+5, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú 2012-07-13 18:44:34
wqssfj1: ½ð±Ò+5, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú 2012-07-13 18:44:34
|
¶Ô²»Æð£¬Óм¸´¦Â©×Ö¡£ÔÌû²»Èøģ¬Ôٻظ´Ò»´ÎÀ²£º ÕâÊÇÁ½¸ö²¢Áеľä×Ó¡£an evaluation....was performed and ¡°Localized exfoliation or blisters¡± were added . ·Ò룺 However, an evaluation of all reports related to skin events received by Novartis from marketed use of vildagliptin (includes Galvus and Eucreas) since the original placing on the market to 29 Feb 2012 was performed ²»¹ý£¬ÒѶÔ×ÔͶ·ÅÊг¡ÒÔÀ´ÖÁ2012Äê2ÔÂ29ÈÕŵ»ª¹«Ë¾ÊÕµ½µÄ¹ØÓÚʹÓÃvildagliptin (°üÀ¨Galvus and Eucreas)ÒýÆðµÄƤ·ô·´Ó¦µÄËùÓб¨¸æ½øÐÐÁËÆÀ¹À£¬ and as post-marketing experience ¡°Localized exfoliation or blisters¡± (frequency not known) were added as the adverse drug reactions in the current CDS. ²¢½«¡°¿ÉÒÔÒýÆð¾Ö²¿ÍÑÆ¤»òË®ÅÝ(¸ÅÂÊδ֪)¡±×÷ΪÊг¡·´À¡ÐÅÏ¢¼ÓÈëĿǰCDSµÄ¸±×÷ÓÃ˵Ã÷ÖС£ |
6Â¥2012-06-28 17:46:36













»Ø¸´´ËÂ¥